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【Abstract】Objective:    Measurement of biomarkers
is a potential approach to early prediction of the risk of
mortality in patients with sepsis. The aim of the present
study was to evaluate the prognostic value of pro-atrial
natriuretic peptide (pro-ANP) and pro-adrenomedullin (pro-
ADM) levels in a cohort of medical intensive care patients
and to compare it with that of other known biomarkers and
physiological scores.
Methods:    Blood samples of 51 consecutive critically ill
patients admitted to the intensive care unit and 53 age-matched
healthy control people were evaluated in this prospective
study. The prognostic value of pro-ANP and pro-ADM levels
was compared with that of acute physiology and chronic
health evaluation (APACHE) II scores and various
biomarkers such as C-reactive protein, interleukin-6 and
procalcitonin. Pro-ANP and pro-ADM were detected by a
new sandwich immunoassay.
Results:    On admission, 25 patients had systemic in-
flammatory response syndrome (SIRS), 12 sepsis, 9 severe
sepsis and 5 septic shock. At that time, the median levels
(ng/ml) of pro-ANP and pro-ADM were 87.22 and 0.34
respectively in patients with SIRS, 1533.30 and 2.23 in
those with sepsis, 1098.73 and 4.57 in those with severe
sepsis, and 1933.94 and 8.21 in those with septic shock.
With the increasing severity of disease, the levels of pro-
ANP and pro-ADM were gradually increased. On admission,
the circulating levels of pro-ANP and pro-ADM in patients
with sepsis, severe sepsis, or septic shock were significantly
higher in non-survivors than in survivors (P<0.05). In a re-
ceiver operating characteristic curve analysis for the sur-
vival of patients with sepsis, the areas under the curve
(AUCs) for pro-ANP and pro-ADM were 0.89 and 0.87
respectively, which was similar to the AUCs for procalcitonin
and APACHE II scores.
Conclusion:    Pro-ANP and pro-ADM are valuable
biomarkers for prediction of severity of septic patients.
Key words:    N-terminal proatrial natriuretic peptide;
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Sepsis is one of the most frequent causes ofdeath in intensive care unit (ICU) patientsworldwide. According to recent reports, the
incidence of sepsis has been rising at a rate of 1.5%-8%
per year.1 About 9% of the sepsis develops to serious
sepsis and 3% to septic shock. Although great progress
has been made in the treatment of sepsis, the mortality
of patients with severe sepsis is still as high as 30%-
70%.2-4 Moreover, the high expenditure of sepsis man-
agement has resulted in a heavy financial burden to the
government and patients.1 Therefore, how to estimate the
severity of sepsis early and apply targeted therapies timely
is very important in the treatment of sepsis.
Blood culture is a gold standard for diagnosis of
infection. However, it takes too long and the rate of
false negative results is relatively high. The specificity
of white blood cell count, C-reactive protein (CRP),
interleukin (IL)-6 and their specific antibody comple-
ments are not significantly high enough for an early
diagnosis of sepsis. There are some disputes about the
distinction between infection and non-infection by
procalcitonin (PCT).5 Especially in the early stage of
sepsis when symptoms are not obvious, though the
patient’s conditions have deteriorated, there are no posi-
tive results in the conventional laboratory test until the
chance for prompt treatment has gone.
Members of the natriuretic peptide family have been
recognized as markers for congestive heart failure.
Defending against hypertension and salt-water retention,
these markers antagonize the renin–angiotensin–aldos-
terone system, exerting influence on sodium reabsorp-
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tion in the renal tubule, vascular tone and cell growth.6, 7
Atrial natriuretic peptide (ANP) is predominantly pro-
duced in the atrium and comprises 98% of natriuretic
peptides in circulation. Most sepsis patients are ac-
companied with cardiovascular dysfunction, mainly pre-
senting as cardiac muscle inhibition, with dysfunction
of contraction and relaxation of the left ventricle par-
ticularly obvious. Adrenomedullin (ADM), a peptide with
52 amino acids, has the effect of immune regulation,
metabolic and vascular activ ities. It is a potent
vasodilator, and its widespread production in tissues
helps to maintain blood supply for individual organs.8
Interestingly, ADM also has bactericidal activity which
can be further enhanced by its regulation and modula-
tion of complement activities.9 Serum levels of ANP and
ADM are shown to be increased in patients with sepsis,
reflecting their involvement in the pathophysiological
process of disease. However, the measurement of
ANP and ADM is technically challenging and reliable
measurement is almost impossible because ANP and
ADM are cleared out rapidly in the circulation. But
their prohormones, pro-atrial natriuretic peptide (pro-
ANP) and pro-adrenomedullin (pro-ADM), which are
secreted at the same molar ratio as ANP and ADM,
have a much longer half-life compared to the mature
ANP and ADM. It has been suggested that pro-ANP
and pro-ADM are more reliable analytes8-11 and they
have a positive correlation with the disease severity and
may become new biomarkers for early diagnosis of
sepsis.12,13 The updated laboratory methods can detect
the indexes above, thus to set a foundation for their clini-
cal application.11,14
In this study, we aimed to further evaluate the prog-
nostic value of pro-ANP and pro-ADM levels in a cohort
of well defined medical ICU patients by comparing with
other biomarkers like IL-6, CRP and PCT and a dis-
ease severity index—acute physiology and chronic
health evaluation (APACHE) II scores.
METHODS
Research design and subjects selection
In the present study, we evaluated the pro-ANP and
pro-ADM levels of 51 consecutive critically ill patients
admitted from June to November 2007 to the medical
ICU, Affiliated First People’s Hospital of Shanghai
Jiaotong University, Shanghai, China. All the medical
and surgical patients were included except those with
neurologic trauma or cardiac operations.
Data on admission day (during the first 24 hours),
the second day, and the day either discharge from ICU
or death were collected. For patients who died within
24 hours after admission, only data on admission day
were collected. Vital signs, clinical status and severity
of disease, and laboratory parameters, including pro-
ANP and pro-ADM levels, were assessed and calcu-
lated each day. The APACHE II scores were calculated
by means of maximal daily deviations of 12 physiologi-
cal variables and corrected with consideration of ages
and various chronic diseases.
Patients were divided into four groups: SIRS, sepsis,
severe sepsis and septic shock, as defined according
to the well known consensus criteria.15 SIRS was char-
acterized by the presence of at least two of the follow-
ing clinical manifestations: fever or hypothermia (>38°C
or <36°C); tachycardia (>90 beats/min); tachypnoea
(>20 breaths/min, PaO2<32 mm Hg or need for me-
chanical ventilation); white blood cell count>12 000 cells/µl
or<4 000 cells/µl, or >10% band forms. Sepsis was
defined as SIRS with an infection which was defined
based on the Society of Critical Care Medicine/Euro-
pean Society of Intensive Care Medicine/American
College of Chest Physicians/American Thoracic Soci-
ety/ Surgical Infection Society (SCCM/ESICM/ACCP/
ATS/SIS) consensus criteria.16 Severe sepsis was de-
fined as the presence of sepsis and at least one of the
following manifestations of organ failure: hypoxaemia
(arterial oxygen tension<75 mm Hg); metabolic acido-
sis (pH<7.30); oliguria (output<30 ml/h); lactic acido-
sis (serum lactate>2 mmol/L); and an acute alteration
in mental status without sedation (reduction by≥ 3
points from the baseline value in Glasgow coma scale
score). Septic shock was defined as the presence of
sepsis accompanied with a sustained decrease in sys-
tolic blood pressure (<90 mm Hg or a drop of 40 mm
Hg from the baseline) despite fluid resuscitation and a
need for vasopressor agent to maintain adequate blood
pressure.
Informed consents were obtained from conscious
patients or their next of kins before enrolment. The pro-
tocol had been approved by the hospital ethics
committee.
For comparison, pro-ANP and pro-ADM levels were
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also measured in 53 cases of age-matched healthy
blood donors.
Methods of measurement
Blood samples were obtained intravenously from the
femoral vein or ulnar vein. Results of routine blood analy-
ses such as complete blood count, serum chemistry
including CRP and blood gas analyses were collected.
Plasma was separated at the moment of blood sam-
pling and frozen at -70°C until further assay. We con-
ducted blind measurement and a batch analysis.
The levels of pro-ANP and pro-ADM were measured
in all patients by an immunoluminometric assay (MR-
proANP LIA; MR-proADM LIA; BRAHMS, AG,
Hennigsdorf, Germany).11,13 Briefly, this assay employed
two polyclonal antibodies specific to pro-ANP (amino
acids 53–90) and pro-ADM (amino acids 45–92). The
minimum detectable concentration in the assay was 0.01
ng/ml. Intraassay imprecision was less than 10% over
the entire measuring range, and the functional assay
(interassay coefficient of variation<20%) could detect a
concentration as low as 0.05 ng/ml. The assay exhib-
ited linear dilution and pooling of samples or addition of
synthetic analyte had no impact on recovery of the
analytes. Stability of the analytes (<20% loss of
recovery) in ethylene diamine tetraacetic acid (EDTA)
plasma was demonstrated for at least 3 days at room
temperature, 14 days at 4°C and 1 year at -20°C.
PCT was measured by a rapid sensitive immunoas-
say (PCT LIA, BRAHMS, AG, Hennigsdorf, Germany).
The minimum measurable concentration in the assay
was 0.01 ng/ml and the functional assay (interassay
coefficient of variation<20%) could detect a concentra-
tion as low as 0.05 ng/ml. CRP was determined by a
routine enzyme immunoassay (hs-CRP, Shanghai
Technology Co. Ltd, Shanghai, China). A serum level
greater than 8 mg/L was considered abnormally
elevated. IL-6 was measured by radioimmunoassay
(IL-6 RIA kit (HY-078), Huaying Technology Co. Ltd,
Beijing, China), and the minimum detectable concen-
tration was 0.6 pg/ml.
Data analysis
Data were expressed as mean±standard deviation
in the study. Comparison of frequencies was done by
the χ 2 test. Comparisons between two groups were
performed  by the non-parametric Mann-Whitney U test
and among multiple groups were conducted by one-
way analysis of variance with least square difference
post-hoc evaluation. A receiver operating characteristic
(ROC) curves analysis was constructed by SPSS 15.0
statistical software. Undetectable levels were assigned
equal to the minimum detectable concentration in the
assay. Correlation analyses were performed by
Spearman rank correlation. To estimate the potential
clinical benefit of pro-ANP and pro-ADM levels, we used
the likelihood ratio test to determine whether logistic
regression models including the measurement of pro-
ANP, pro-ADM and routine clinical parameters such
as APACHE II score could provide a greater signifi-
cance than logistic regression models limited to
APACHE II score alone. All statistical tests were two-
tai led and P<0.05 was considered statistically
significant.
RESULTS
Characteristics of study subjects
Blood samples of 51 patients were collected. The
mean age of these 51 patients was (54.3±20.7) years
with a range of 17 to 90 years. The percentage was
53% for male patients and 47% for female patients.
Thirty-four patients had other medical problems, and
17 had surgeries before. Detailed baseline characteris-
tics of the study population are summarized in Table 1.
Correlation between pro-ANP, pro-ADM and sever-
ity of disease
Comparisons of po-ANP and pro-ADM concentra-
tions on admission among each patient group and the
control group are showed in Figure 1. The concentra-
tions (ng/ml, range) of pro-ANP and pro-ADM in the
healthy control group were 32.21 (4.35-67.46) and 0.14
(0.01-0.63) respectively. In patients with SIRS, sepsis,
severe sepsis or septic shock, the pro-ANP concen-
trations were 87.22 (34.35-184.21), 533.30 (76.02-1419.23),
1061.70 (135.65-2822.00) and 1933.95 (171.93-3822.60)
respectively. And corresponding values for pro-ADM
concentrations were 0.35 (0.01-0.83), 2.08 (1.09-3.83),
4.23 (2.01-8.34) and 7.63 (3.08-13.80) respectively. Ac-
cording to the clinical severity of infection from SIRS to
septic shock, pro-ANP and pro-ADM levels gradually
increased (P<0.05). Post-test analyses revealed a sig-
nificant difference (P<0.05) in patients with SIRS, sep-
sis or severe sepsis as compared with patients with
septic shock.
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Relation between pro-ANP, pro-ADM levels and out-
comes in patients with sepsis, severe sepsis or
septic shock
All pro-ANP and pro-ADM values of survivors and
non-survivors with sepsis, severe sepsis or septic shock
measured during hospitalization in the ICU are shown
in Figure 2. The median pro-ANP and pro-ADM values
in non-survivors were significantly higher than in survi-
vors in respective groups, and this phenomenon was obvi-
ous on the first day of admission to the ICU (P<0.05). In
contrast, the differences of PCT (P=0.08), CRP (P=0.75),
and IL-6 (P=0.14) between survivors and non-survivors
on the first day of admission were not significant. In
patients without infections, the mean pro-ANP values
(ng/ml, range) in non-survivors were not higher than in
survivors: 82.92 (25.65-137.09) vs 104.10 (41.97-167.41),
P=0.22 for all time points and 101.34 (37.52-149.84) vs
128.96 (38.30-169.04), P=0.56 on admission. Similarly,
pro-ADM values of patients without infections were not
higher in non-survivors than in survivors: 0.35 (0.07-0.57)
vs 0.52 (0.18-1.39), P=0.11 for all time points and 0.36
(0.11-0.97) vs 0.60 (0.24-1.83), P=0.11 on admission.
To define an optimal decision threshold for pro-ANP
and pro-ADM values in septic patients, we performed
ROC plot analysis on data from patients with sepsis,
severe sepsis, or septic shock obtained within the first
48 hours after admission to the ICU. Sensitivity was
calculated among non-survivors, and specificity was
assessed among those discharged from ICU. For
comparison, the same ROC plot analysis was performed
on CRP, PCT, IL-6 and APACHE II scores. The areas
under the curve (AUCs) were 0.89 for pro-ANP and 0.87
for pro-ADM, significantly higher than those for IL-6 (0.71)
and CRP (0.53), but similar to those for PCT (0.81) and
APACHE II score (0.81, Figure 3). The AUC for pro-ANP
combined with pro-ADM was 0.92, which exceeded that
of either peptide alone. The optimal threshold concen-
tration of pro-ANP was 150.0 ng/ml. At this cutoff, the
sensitivity for correct prediction of death in the ICU was
87% and the specificity was 86%. The optimal thresh-
old concentration of pro-ADM was 0.80 ng/ml. At this
cutoff, the sensitivity was 91% and specificity was 73%,
respectively. The PCT and APACHE II scores were also
predictive for prognosis but they had much lower val-
ues as compared with pro-ANP and pro-ADM. At a PCT
threshold of 0.55 ng/ml, the sensitivity was 76% and
specificity was 81%. At an APACHE II threshold of 23.5,
the sensitivity was 80% and specificity was 76%. At a
PCT threshold of 25 ng/ml, which was recommended by
the US Food and Drug Administration for the use of
activated protein C, the sensitivity was 63% and specific-
ity was 78%. When the level of pro-ANP combined with
pro-ADM was 151.0 ng/ml, the sensitivity was 90% and
specificity was 89%.
DISCUSSION
We found a significant increase of plasma pro-ANP
and pro-ADM concentrations in septic patients, espe-
Table 1. Baseline characteristics of 51 patients
Characteristic                                                        n
SIRS
   Pneumonia                                                           2
   Chronic obstructive pulmonary disease              2
   Heart failure                                                        1
   Myocardial infarction                                           1
   Renal failure                                                        1
   Acute pancreatitis                                               2
   Portal vein thrombosis                                         1
   Trauma                                                              13
   Cerebral hemorrhage                                          1
   Paraquat poisoning                                             1
Sepsis
   Spontaneous pneumothorax                               1
   Pneumonia                                                           2
   Chronic obstructive pulmonary disease              4
   Renal failure                                                        1
   Acute pancreatitis                                               1
   Alimentary tract hemorrhage                               1
   Liver abscess                                                     1
Severe sepsis
   Pneumonia                                                           1
   Chronic obstructive pulmonary disease             3
   Infective shock                                                    1
   Chronic glomerulonephritis                                  2
   Acute pancreatitis                                               1
   Alimentary tract perforation                                1
Septic shock
   Chronic obstructive pulmonary disease             1
   Alimentary tract perforation                                 2
   Alimentary tract tumor                                         2
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As generally recommended, sepsis, severe sepsis
and septic shock are diagnosed based on the consen-
sus criteria defined by ACCP/SCCM in 1991. However,
many clinicians believe that the criteria are not sensi-
tive and can easily lead to misdiagnosis because they
cannot show the pathophysiological process, state and
course of disease. Thus, a new sepsis diagnostic cri-
terion was defined at an international conference held
in Washington in 2001. However, perfect gold standards
for diagnosis of infections still do not exist, and clinical
classification of critically ill patients is not 100% defi-
nite despite the use of these guidelines. An ideal sep-
sis marker should be able to guarantee an early
diagnosis, predict the course of disease, and help to
differentiate bacterial causes from noninfectious and viral
causes of systemic inflammation, not only in sepsis
trials but also in routine clinical application.
Sepsis is a complex syndrome including coagula-
tion disorder, inflammatory response, cellular disorder
and metabolic alteration.18 The ambiguity of clinical di-
agnosis and risk stratification are major problems in
cially those did not survive in the end, as compared
with critically ill patients without infection. More impor-
tantly, on the first day of admission to the ICU, levels of
pro-ANP and pro-ADM, not other markers of infection
and inflammation such as CRP, IL-6, and PCT, were
significantly increased in non-survivors as compared with
survivors, suggesting that pro-ANP and pro-ADM are
better in predicting the severity of sepsis patients. At a
threshold of 150.0 ng/ml, pro-ANP had the sensitivity
of 87% for death prediction of ICU sepsis patients, and
specificity of 86%. At a threshold of 0.80 ng/ml, pro-
ADM had the sensitivity of 91% for death prediction of
ICU sepsis patients, and specificity of 73%. These en-
couraging figures have not been found in any other
tested biomarkers.
During infection, the increase of bacterial endotoxin
and proinflammatory cytokines leads to a higher inci-
dence of congestive heart failure, meanwhile, because
of inadequate organ perfusion, the clearance of ANP
and pro-ANP is decreased, which results in an obvious
increase of ANP and pro-ANP levels in septic patients.17
There might be two mechanisms responsible for the
marked increase of pro-ADM and mature ADM levels in
circulation in sepsis. (1) As a member of calcitonin re-
ceptor-like receptor gene family, pro-ADM is widely
expressed and extensively synthesized during sepsis.7
And partly (2) the clearance of pro-ADM by the kidney
and lung is decreased.
Figure 2. Comparisons of levels of pro-ANP (A) and pro-ADM
(B) on admission between survivors and non-survivors. Pa-
tients were grouped according to the clinical diagnosis of sepsis
based on international guidelines. For both pro-ANP and pro-ADM,
*P<0.001, compared with the survivors.
Figure 1. Levels of pro-ANP (A) and pro-ADM (B) on admission in
healthy control individuals and patients with SIRS, sepsis, severe
sepsis or septic shock. For both pro-ANP and pro-ADM, *P<0.001,
compared with the controls.
Figure 3. ROC plot analysis of different biomarkers with respect
to outcome prediction of sepsis. Data were from patients grouped
by the clinical diagnosis of sepsis according to international guide-
lines on admission.
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sepsis management. In the past, almost all interven-
tion trials failed to show any benefit from therapies for
sepsis, and thus sepsis intervention has been referred
to “graveyard for pharmaceutical companies”.19,20
Therefore, to find a better biomarker to direct the clinical
treatment of sepsis is urgent. APACHE II scores, which
synthesize 12 acute physiological and chronic health
status parameters,serve to assess the severity of dis-
ease and associate closely with prognosis. In the
present study, the prognostic value of pro-ANP and pro-
ADM levels is comparable to that of PCT and APACHE
II scores. More importantly, pro-ANP and pro-ADM lev-
els are easier to determine and furthermore can reflect
the significant pathophysiological changes in sepsis.
The limitation of our study is that only 51 patients
are included in this trial. We consider that our results
are prospective but need to be validated in more patients.
If our findings can be further confirmed, pro-ANP and
pro-ADM may become the new promising biomarkers
for prognosis and individual risk stratification of sepsis.
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